Retatrutide Pen Guide: Specifications & Research Handling
This documentation-led retatrutide pen guide is for laboratories, researchers and institutional personnel in the UAE who handle the 30mg prefilled research format. It covers the pen’s format and documented composition, its device specifications, retatrutide pen storage from delivery to the lab fridge, batch proof and the handling records a lab keeps. It also marks the boundary between published clinical-trial evidence and research-product handling. It does not provide priming, injection, administration, titration, or personal-use instructions, because in laboratory settings peptide integrity and consistent research results depend on handling, storage, and documentation being followed exactly.
For format selection, compare retatrutide 30mg pen prices and stock in the UAE, other pen sizes, or vials and kits. Each product page lists that format’s specifications and ordering options.
Update History ▾
November 3, 2026: Added sections on how retatrutide works on the GLP-1, GIP and glucagon receptors and on where it stands in clinical trials (figures as on the trial tracker and approval status pages), a pen-versus-vial comparison table, and links to the 30mg pen, the retatrutide vials and both calculators. Specifications, storage and the no-administration boundary are unchanged.
October 24, 2026: Added direct comparisons for 30mg pens, other pen sizes, and vials and kits; linked delivery information to the delivery policy. Device and research-handling guidance is unchanged.
October 23, 2026: Storage pass. The introduction now says who the guide is for and what it covers. The storage section answers whether the pen needs chilling, how long it lasts in the fridge and what UAE heat means for delivery and receipt, and lists when to set a pen aside, citing the ICH Q1A(R2) stability guideline and three peer-reviewed stability reviews. Added Lilly’s approval status, a batch-traceability note, the label rule for the dual-chamber and Genovare pens and two storage FAQs.
October 14, 2026: Applied the owner’s Surfer edits: the H1 now reads “Retatrutide Pen Guide”, the introduction names the audience and why handling must follow documentation, the scope note covers pen-versus-vial formats, the specifications heading adds pen needles, and the storage list is headed “Before First Use: Injection Sites”.
October 12, 2026: Corrected the Lancet 2022 phase 1b reference (Urva et al., not Frias et al.), corrected the Rosenstock 2023 title, removed an uncited pharmacopeia reference, aligned the structured-data citations with the visible sources and renamed the approval-status link to Lilly’s planned BLA. This entry also records an earlier change that the log did not list: the six-step walkthrough and the priming and administration FAQs from the June 10 rewrite were removed when the page was reframed around specifications, storage and documentation (dated July 23, 2026). The page gives no priming, injection or administration instructions.
June 10, 2026: Rewrote around the "how to use" question with a natural six-step pen walkthrough (prepare, attach needle, prime, dial, inject, store), added priming and "what happens if it gets warm" FAQs, and retitled for how-to intent. Kept research-use framing; dosing schedule and mg-to-click math stay in the dosage and clicks guides.
June 6, 2026: Retitled for research-handling intent, tightened RUO snippet language, and replaced instruction-style FAQ wording with device documentation context.
June 1, 2026: Shortened SERP title, softened handling language, and aligned supporting feed and LLM summaries after Surfer review.
May 25, 2026: Aligned dateModified and routed device-specific readers to the retatrutide research hub for trials, approval status, dosing, and Dubai context.
May 24, 2026: Removed 28-day in-use window references across subtitle, key specs, storage table, body, FAQ, and JSON-LD
May 24, 2026: Retitled for "how to use retatrutide pen" keyword; tightened Step 5 with receptor mechanism, added once-weekly research-protocol framing, refreshed pen-vs-vial comparison
April 26, 2026: Refreshed structure with administration steps, pen-vs-vial comparison, and storage clarifications
April 14, 2026: Removed click-table overlap, stripped commercial routing, and tightened the page around hardware, storage, priming, and needle fit
April 13, 2026: Tightened device-first positioning, clarified calculator versus clicks-chart routing, and refreshed the storage/priming promise
April 8, 2026: Repositioned the page around pen mechanics, storage, and handling rather than general dose-planning
March 14, 2026: Initial publication
Research summary
The page describes the listed 30 mg retatrutide pen as a prefilled research device and gathers its composition, storage information and batch documentation. Specifications and compatibility must be checked against the current product lot and device documentation. Lilly describes retatrutide as investigational; clinical trial findings do not validate this separate device or define its handling.[6] [7]
- For in-vitro laboratory research only.
- Follow the institution's authorised laboratory SOP; this summary is not administration guidance.
Summary revised November 1, 2026. This editorial update does not constitute a new literature review.
What Is the Retatrutide Pen Format?
The retatrutide pen is a prefilled liquid research format with a nominal 30mg content and 300-click device scale. Unlike a lyophilised vial, it does not require a reconstitution step. The nominal scale is a product specification; current lot and device documentation control the actual dispensing calibration and compatible laboratory accessories.
Retatrutide (LY3437943) is Eli Lilly’s investigational triple agonist of the GIP, GLP-1 and glucagon receptors. Lilly says it has not been approved by any regulatory agency, and Lilly plans to submit retatrutide for US approval in Q1 2027.[6][7]
This guide documents hardware identity, composition, storage and evidence sources. It does not translate published trial schedules into product-use instructions or provide priming, injection, accessory-selection or mg-to-click guidance.
Published Phase 2 and Phase 3 trials used protocol-controlled administration by study teams.[1][3] Those clinical procedures are reported as historical evidence and do not establish a handling protocol for a Remy Research research product.
Evidence and context
The 30mg retatrutide pen is a prefilled research device containing 30mg total across a nominal 300-click device scale. Composition, storage and batch proof are documented here. Dispensing, accessory compatibility and handling must follow the current lot/device documentation and an authorised institutional laboratory SOP; this page does not provide priming, injection, administration, titration or personal-use instructions.
- 30mg total retatrutide per pen
- 300 clicks per pen
- 0.1mg nominal material increment
- Lot/device documentation controls dispensing calibration
- No administration or personal-use instructions
Additional context
Additional context
Scope note: this guide covers documented device specifications, storage, batch proof and research-handling boundaries, including how the pen differs from lyophilised vial formats. It does not provide a clinical schedule, administration procedure, or product-quantity calculation.How Does Retatrutide Work on GLP-1, GIP and Glucagon Receptors?
Retatrutide is an investigational triple receptor agonist from Eli Lilly: a single molecule that activates three hormone receptors, the glucose-dependent insulinotropic polypeptide (GIP) receptor, the GLP-1 receptor and the glucagon receptor. In published clinical research, GLP-1 receptor activity is linked to glucose-dependent insulin release, slower gastric emptying and decreased appetite. GIP receptor activity is studied for how it adds to those GLP-1 effects, the basis of dual agonist compounds such as tirzepatide.
Glucagon receptor activity is the third arm. It is studied for energy expenditure and liver fat metabolism, which is why retatrutide also appears in fatty liver disease research. These findings describe the molecule in trials; they do not describe this pen or how to handle it. For the full receptor picture, see the GLP-1, GIP and glucagon mechanism guide and the retatrutide profile.
What Are the Pen Specifications and Pen Needles?
The retatrutide 30mg pen is a prefilled research device. The specification rows below separate nominal composition and scale from the documentation that controls laboratory handling.
| Specification | Detail |
|---|---|
| Format | Prefilled Pen |
| Total Content | 30mg retatrutide |
| Total Clicks | 300 clicks |
| Nominal material increment | 0.1mg per scale increment |
| Dispensing calibration | Use current lot and device documentation |
| Intended use | In-vitro laboratory research only |
| Accessory compatibility | Controlled by current device documentation and institutional SOP |
| Storage (unopened) | 2–8°C (refrigerated) |
| Storage (in use) | Refrigerated (2–8°C) — return after each use |
The device scale is a product specification, not an administration schedule. Do not infer a use protocol from the nominal content or click count.
What Controls Research Handling?
The pen is a prefilled research format. Handling, dispensing calibration, compatible laboratory accessories, storage limits, and disposal must follow the current lot documentation, device documentation, and an authorised institutional laboratory SOP. Remy Research does not provide priming, needle-selection, injection, administration, or personal-use instructions.
Published retatrutide trials used protocol-controlled subcutaneous administration by study teams. That historical fact is reported as clinical evidence only and does not establish a use procedure for a research-use product.
Which Sources Control the Device Record?
Use the current product specification and batch documentation for composition and verification, and the current lot/device documentation plus institutional SOPs for laboratory handling. Published clinical-trial schedules belong to the cited study records and are not converted here into product clicks, quantities, or administration steps.
The certificate of analysis (COA) for the Remedium Research 30mg pen is the Janoshik HPLC report for batch RETP002.[2] Write the batch number (some labels call it the lot number) from the pen’s label into the storage log next to that COA reference, so every storage note traces back to a named batch.
How Does a Pen Differ from a Lyophilised Vial?
A prefilled pen and a lyophilised vial are different laboratory formats. The pen is supplied as a sealed liquid device; the vial is a dry research material whose preparation and handling depend on its batch documentation and the institution's SOP. This page does not rank formats by personal convenience or translate either format into administration instructions.
Current ZPHC-labelled pen references include the Retatrutide AQ 30mg pen and Retatrutide 60mg dual-chamber pen. Lyophilised ZPHC references are listed separately as the 15mg vial and the 10mg, 20mg, 40mg, 60mg, and 120mg multi-vial kits. Each product page carries its own live price, stock, format, and evidence boundary.
Storage follows each pen’s own label. The ZPHC dual-chamber pen keeps dry powder and sterile water in separate chambers, so its peptide is not in solution during transit and storage; the storage guidance on its original box applies. Genovare’s retatrutide AQ pens are premixed aqueous pens, stored as the Genovare pack label directs. That includes RETAKLIK 2.0, Genovare’s pen that combines 30mg of retatrutide with 5mg of cagrilintide.
| Factor | Prefilled pen | Lyophilised vial |
|---|---|---|
| Supplied as | Sealed liquid in a prefilled device | Dry powder in a sealed vial |
| Before first use | No reconstitution step | Reconstitution under the institution’s SOP |
| Scale | Nominal 300-click scale on the 30mg pen; current device documentation controls calibration | Set by the laboratory’s own preparation SOP |
| Storage | 2–8°C, never frozen, protected from light | As stated on the lot documentation |
| Batch proof | Lot COA, for example RETP002 | Lot COA |
For the 30mg pen itself, see the Remedium Research 30mg retatrutide pen; for the lyophilised format, see the 10mg and 40mg retatrutide vials. To convert a pen’s nominal click scale into listed material, use the retatrutide pen clicks to mg calculator; for vial units, use the retatrutide calculator. For retatrutide cost by format, see the Dubai pricing guide, and to buy retatrutide pens or vials for laboratory and research purposes, see Retatrutide UAE.
How Should a Retatrutide Pen Be Stored in the UAE?
Knowing how to store a retatrutide pen protects peptide integrity and keeps research results consistent. Retatrutide degrades when exposed to heat, light, or repeated freeze-thaw cycles, so the cold chain matters from delivery onward.
Does a Retatrutide Pen Need to Be Kept Chilled?
Yes. Proper storage for the 30mg pen, as its product page lists, is 2–8°C with the cold chain maintained, no freezing and protection from light. The pen holds retatrutide as a liquid solution, so it must never be frozen. That band is standard refrigerator temperature. It is also the long-term storage condition (5°C ± 3°C) that the ICH Q1A(R2) stability guideline uses for products meant for a refrigerator, and for those products the guideline sets 25°C at 60% relative humidity as the accelerated condition.[8] Accelerated conditions are exaggerated storage settings chosen to speed up degradation, so for a refrigerated product, ordinary room temperature already counts as stress.
Before First Use: Injection Sites
- Store at 2–8°C (standard refrigerator temperature)
- Do not freeze — freezing can damage the peptide structure and the pen mechanism
- Keep in original packaging to protect from light
- Store upright if possible
After First Use
- Always return to refrigerated storage (2–8°C) after each use — do not store at room temperature
- Do not expose to temperatures above 30°C
- Avoid direct sunlight or prolonged UV exposure
- Follow the current device documentation and institutional SOP for closure and storage
So what happens if a retatrutide pen gets warm? Brief room-temperature exposure during use is expected, but sustained heat above 30°C or direct sun accelerates degradation — a pen left in a hot car or shipped without a cold chain should be treated as compromised. For underlying peptide degradation kinetics, see the peptide stability and storage guide. In hot climates such as the UAE — where ambient temperatures regularly exceed 45°C — temperature-controlled transport and refrigerated storage are non-negotiable. The delivery policy covers Dubai dispatch and transport, and the broader UAE peptide catalog lists every research compound currently in stock.
How Long Does a Retatrutide Pen Last in the Fridge?
How long a pen keeps in the fridge is set by its own label and lot documentation, with the pen held at 2–8°C and never frozen. Expiry differs by brand, format and batch, and day counts quoted online for other pen products do not carry over to this one.
Retatrutide Pen Storage in UAE Heat: Transport and Receipt
Remy Research sends products that need refrigeration in insulated cold-chain packaging intended to keep them at 2–8°C during delivery, with a live tracking link once the order is dispatched. Dubai orders placed before 4 PM arrive the same day, and orders outside Dubai placed before 12 PM (noon) arrive the next day; the delivery page lists the weekend exceptions. The weak point is the time between the doorstep and the fridge.
- Move the pen into a 2–8°C refrigerator first, then fill in the delivery receiving checklist: delivery time, carton and seal condition, the batch number on the label and any temperature reading
- In an insulated case, keep the pen out of direct contact with cold packs so it cannot freeze
- Do not leave a pen in a parked car or on a doorstep in a UAE summer, even for a short time
When Should a Pen Be Set Aside?
Treat a pen as compromised and note it in the storage log if any of these apply:
- It has been frozen, even once
- It sat above 30°C or in direct sun
- Its solution has turned cloudy, changed colour or shows visible particles since it arrived
- It is past the expiry date on its label
The science behind these checks comes from general peptide and protein research; none of it was measured on this pen. Freezing exposes a protein solution to low temperature, freeze-concentration and ice crystal formation, the three chief stresses that can cost it biological activity.[9] Light can photo-oxidise protein residues such as tryptophan, tyrosine, phenylalanine and cysteine.[10] Peptides in solution can also self-associate into amorphous aggregates or fibrils, and temperature and agitation are among the factors that influence it.[11] A visual inspection catches only gross changes. It cannot confirm peptide content, which is what the batch documentation records.
Where Is Retatrutide in Clinical Trials?
Retatrutide is still undergoing clinical trials and is not an approved medicine anywhere. In the pivotal Phase 3 TRIUMPH-1 obesity trial (topline reported by Lilly on May 21, 2026; published in the New England Journal of Medicine on September 29, 2026), participants on the 12 mg dose had a mean 28.3% reduction in body weight at 80 weeks on the efficacy estimand, or 25.0% under the treatment-regimen estimand.[12] TRIUMPH-2 and TRIUMPH-3, the latter an 80-week weight trial in people with established cardiovascular disease, reported positive topline results on 23 July 2026.[7] Eli Lilly plans to submit retatrutide for US approval in the first quarter of 2027; no submission or PDUFA date exists yet.[6]
Commonly reported adverse events in the trials were gastrointestinal. These are results for Lilly’s drug product under trial protocols and do not validate this research pen. Follow the TRIUMPH trial tracker, the approval status page and the side-effects review for updates.
Our Research Standards for Research Peptides
This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →
Sources
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. nejm.org
- Janoshik Analytical — Certificate of Analysis, Batch RETP002. HPLC purity: 99.262%. remyresearch.com/coa/retp002/
- Eli Lilly. TRIUMPH Clinical Trial Program for Retatrutide. clinicaltrials.gov ↩
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi.org/10.1016/S0140-6736(23)01053-X
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. PMID 36354040. doi.org/10.1016/S0140-6736(22)02033-5
- Eli Lilly and Company. What to know about retatrutide. lilly.com, September 29, 2026. lilly.com
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. Press release, July 23, 2026. investor.lilly.com
- ICH. Q1A(R2) Stability Testing of New Drug Substances and Products. Step 4 version, 6 February 2003. Storage conditions for products intended for storage in a refrigerator, and the glossary definition of accelerated testing. database.ich.org
- Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505–523. PMID 17963151. doi.org/10.1080/10837450701481157
- Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468–1479. PMID 17230445. doi.org/10.1002/jps.20815
- Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. PMID 29147559. doi.org/10.1098/rsfs.2017.0030
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. Published online September 29, 2026. doi:10.1056/NEJMoa2604169. doi.org/10.1056/NEJMoa2604169